HC Wainwright Predicts Reduced Earnings for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – HC Wainwright reduced their FY2026 EPS estimates for shares of Xeris Biopharma in a note issued to investors on Friday, August 7th. HC Wainwright analyst B. Folkes now expects that the company will earn $0.04 per share for the year, down from their prior estimate of $0.07. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Xeris Biopharma’s FY2028 earnings at $0.33 EPS, FY2029 earnings at $0.65 EPS and FY2030 earnings at $0.92 EPS.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 158.10%. The firm had revenue of $92.10 million during the quarter, compared to analyst estimates of $90.12 million.

XERS has been the subject of a number of other reports. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings raised Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Xeris Biopharma currently has an average rating of “Moderate Buy” and an average price target of $10.80.

Xeris Biopharma Price Performance

Shares of NASDAQ XERS opened at $7.99 on Tuesday. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The business’s 50 day moving average price is $7.72 and its two-hundred day moving average price is $6.80. The company has a market cap of $1.38 billion, a PE ratio of -72.64 and a beta of 0.66. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $10.08.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently modified their holdings of XERS. BlackRock Inc. bought a new stake in shares of Xeris Biopharma in the second quarter valued at about $115,042,000. Vanguard Group Inc. increased its position in Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after acquiring an additional 1,358,760 shares during the period. Geode Capital Management LLC increased its position in Xeris Biopharma by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after acquiring an additional 135,815 shares during the period. State Street Corp raised its stake in Xeris Biopharma by 10.1% in the 4th quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after purchasing an additional 378,595 shares in the last quarter. Finally, Qube Research & Technologies Ltd raised its stake in Xeris Biopharma by 6.0% in the 3rd quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after purchasing an additional 185,063 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Insider Buying and Selling

In related news, Director Dawn Halkuff sold 20,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $6.09, for a total transaction of $121,800.00. Following the completion of the sale, the director directly owned 95,000 shares of the company’s stock, valued at approximately $578,550. This trade represents a 17.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 90,000 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the sale, the insider owned 1,691,126 shares of the company’s stock, valued at $13,579,741.78. This trade represents a 5.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 266,499 shares of company stock valued at $1,996,417 in the last ninety days. 4.35% of the stock is currently owned by company insiders.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.